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Virus replication requires lipid metabolism, but how lipids mediate virus infection remains obscure. In this
issue, Amini-Bavil-Olyaee et al. (2013) reveal that IFITM proteins disturb cholesterol homeostasis to block
virus entry. Previously, inCell, Morita and colleagues (2013) showed the antiviral potency of the lipidmediator
protectin D1.Viruses are obligate intracellular parasites
and crucially depend on host cell
machineries for efficient replication. Virus
replication is a complex interplay
between host and viral factors, in which
cellular metabolic homeostasis can be
disrupted to generate energy and macro-
molecular precursors for efficient virus
production. For example, modulation of
de novo fatty acid and lipid biosynthesis
represents a common feature of virus
replication (Chukkapalli et al., 2012). In
particular, enveloped viruses consisting
of a host-derived lipid bilayer interfere
with host cell lipid metabolism and hijack
membrane lipid domains for biogenesis
of their envelopes. Besides being media-
tors of virus replication and assembly/
budding, host lipids in virus envelopes
are also indispensable for structural integ-
rity and functionality of virions. Enrich-
ment of certain lipids in virus envelopes
ensures maintenance of biophysical
characteristics such as membrane
fluidity (cholesterol) and membrane cur-
vature (phopshatidylethanolamine [PE]),
which are important for membrane fusion
during virus infection into host cells.
Therefore, the enormous structural and
functional diversities of lipids highlight
their great potential as attractive targets
for host-virus interactions at various life
cycle stages. For example, tens of thou-
sands of different lipid species are
estimated to exist; aggregates of lipids
can form plasma membrane microdo-
mains, and lipid droplets implicated in
cell signaling, trafficking and storage,
and single entities can act by way of
inflammatory mediators such as platelet-
activating factor and eicosanoids (Wenk,
2010).In this issue, Amini-Bavil-Olyaee and
colleagues unveil an intriguing antiviral
mechanism of how perturbations in host
cell cholesterol homeostasis block viral
entry (Amini-Bavil-Olyaee et al., 2013).
They show that interferon-inducible trans-
membrane proteins (IFITMs) exert their
antiviral activity by mediating the accu-
mulation of cholesterol in late endosomal
compartments. IFITMs are a group of
interferon-stimulated genes (ISGs), identi-
fied in many genome-wide siRNA
screens, which block entry of a plethora
of viruses along the endosomal trafficking
pathway. A single-nucleotide polymor-
phism (SNP) of IFTIM3 correlated with
increased morbidity in influenza-infected
patients, demonstrating the biological
significance of IFITM3 in restricting virus
pathogenesis (Everitt et al., 2012; Zhang
et al., 2013). Therefore, dissecting and
understanding the fundamental mecha-
nisms of how IFITMs mediate their anti-
viral activity is of substantial interest.
Using a yeast two-hybrid assay, the au-
thors first identified vesicle-associated
membrane protein (VAMP)-associated
protein A (VAPA) as cognate interaction
partner for IFITM3. Although it is not
obvious how the implicated transmem-
brane domain interactions between
IFITM3 and VAPA could initially be de-
tected by a yeast two-hybrid assay, the
veracity of this IFITM3-VAPA interaction
is borne out by a plethora of downstream
specificity and functional experiments.
VAPA is implicated in endosomal
cholesterol homeostasis through its inter-
action with oxysterol-binding protein
(OSBP). The VAPA-OSBP complex medi-
ates the transport of de novo synthesized
cholesterol from the endoplasmic reticu-Cell Host & Microbelum (ER) to other intracellular organelles.
The authors further revealed that
increasing IFITM3-VAPA interaction
antagonized formation of VAPA-OSBP
complexes. In combination with confocal
microscopy, the authors concluded that
IFITM3-mediated disruption of VAPA-
OSBP interaction is the underlying cause
of cholesterol accumulation in late endo-
smal compartments, which consequently
inhibits virus entry (Figure 1). Through a
series of impressive electron microcopy
experiments, the authors conclusively
demonstrated the IFITM3-mediated anti-
viral activity of cholesterol accumulation
on vesicular stomatitis virus (VSV) and
influenza virus entry. Intriguingly, two in-
dependent studies recently reported that
host cells evolved a sterol-based antiviral
strategy, whereby interferon-induced
production of the natural oxysterol 25-hy-
droxycholesterol (25HC) inhibits entry of
enveloped viruses (Blanc et al., 2013; Liu
et al., 2013). Considering evidence of
25HC-mediated translocation of OSBP
from the ER to the Golgi (Goto et al.,
2012) (Figure 1), it will thus be interesting
to decipher whether the IFITM3-VAPA-
mediated antiviral activity identified by
Amini-Bavil-Olyaee and colleagues is
part of a complex innate immune pathway
interfering with cholesterol homeostasis
to inhibit virus entry.
The findings by Amini-Bavil-Olyaee
and colleagues were consistent with
impaired intraendosomal trafficking in
cholesterol-laden late endosomal com-
partments and suggested that antiviral
activity of IFITM3 is specific for viruses
fusing and penetrating at late endosomal
membranes. This observed specificity rai-
ses an interesting idea considering the13, April 17, 2013 ª2013 Elsevier Inc. 375
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Figure 1. IFITM Proteins Inhibit Virus Fusion by Cholesterol
Aaccumulation in Late Endosomal Compartments, and PD1 Blocks
Nuclear Export of Viral RNAs
IFITM3 expressed at late endosomal compartments (LE) interacts with vesicle-
associatedmembrane protein (VAMP)-associated protein A (VAPA), disrupting
the endoplasmic reticulum (ER) resident complex between oxysterol binding
protein (OSBP) and VAPA. 25-hydroxycholesterol (25HC) mediates the trans-
location of OSBP to the Golgi, and together these intracellular changes lead to
cholesterol accumulation in LE, blocking virus entry. The docosahexaenoic
acid (DHA)-derived lipid mediator protectin D1 (PD1) inhibits nuclear export
of viral RNAs mediated by NXF1. Biosynthesis of DHA is crucially dependent
on peroxisomal b-oxidation catalyzed by hydroxysteroid (17-beta) dehydroge-
nase 4 (HSD17B4). Influenza virus NS1 antagonizes metabolism of DHA-
derived lipid mediators by its inhibitory interaction with HSD17B4. Host
factors, viral factors, and interferon-stimulated factors are colored in blue,
red, and green, respectively; arrows indicate activation/stimulation or inhibi-
tion (rounded ends). Plasma membrane, PM; early endosome, EE; late endo-
some, LE; endoplasmic reticulum, ER; nucleus, N; peroxisome, P.
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lipids across intracellular
membranes. For example,
cholesterol is markedly en-
riched at the plasma mem-
brane, but its enrichment
gradually decreases along
the endosomal trafficking
pathway. While Amini-Bavil-
Olyaee and colleagues pro-
vide coherent evidence that
virus fusion at late endosomal
compartments is inhibited by
cholesterol accumulation,
previous studies implied that
cholesterol stimulates entry
of viruses such as HIV that
fuse at the plasmamembrane
and/or at early endosomal
compartments. Therefore,
one could envision that
different lipid requirements
during virus entry correlate
with the diverse entry path-
ways hijacked by several
viruses.
A recent report in Cell
(Morita et al., 2013) also un-
derscores the biological sig-
nificance of host cell lipid
metabolites as modulators
of virus infections. Harness-
ing a bioactive lipid screen,Morita and colleagues first observed a
potent inhibition of influenza virus replica-
tion by the omega-3 polyunsaturated fatty
acid (PUFA)-derived lipid mediator pro-
tectin D1 (PD1). They subsequently per-
formed lipidomics analyses and quanti-
fied over 250 endogenous PUFA-derived
lipid mediators in lungs of influenza vi-
rus-infected mice, revealing a strong
reduction of PD1, which correlated with
virus pathogenicity. Remarkably, PD1
treatment protected against severe influ-
enza in vivo, even 48 hr postinfection
when administrated in combination with
peramivir. These findings collectively
highlighted the therapeutic potential and
antiviral activity of PD1, which is synthe-
sized from docosahexaenoic acid (DHA)
by the key enzyme arachidonate 15-lipox-
ygenase (ALOX15 or 12/15-LOX). Surpris-
ingly, its antiviral activity on influenza virus
replication was not due to its possible
anti-inflammatory capacities. Instead,
the authors elegantly discovered a novel
PD1-mediated antiviral mechanism inhib-
iting nuclear export of virus RNAs. Their376 Cell Host & Microbe 13, April 17, 2013 ªresults showed that PD1 inhibited the
direct interaction between viral RNAs
and the mRNA exporter NXF1, which, in
cooperation with the key docking protein
Nup62, facilitates nuclear export of influ-
enza virus RNAs (Figure 1). However, the
precise inhibitory mechanism of PD1,
and especially how influenza virus inter-
feres with PD1 production, still remains
unclear.
Considering the multifunctional nature
of influenza virus nonstructural protein 1
(NS1) in mediating virus replication, inhib-
iting host lipid metabolism, and antago-
nizing the host immune response, it would
not be surprising if NS1 functionally
intersects with DHA/PD1 metabolism.
Peroxisomal b-oxidation catalyzed by
hydroxysteroid (17-beta) dehydrogenase
4 (HSD17B4) is vital for the retroconver-
sion step in DHA biosynthesis. Interest-
ingly, a direct interaction between NS1
and HSD17B4 has been previously re-
ported, and overexpression of HSD17B4
inhibited influenza virus protein expres-
sion (Wolff et al., 1996), consistent with2013 Elsevier Inc.PD1-mediated impairment of
nuclear export. These obser-
vations are further supported
by recent siRNA screens iden-
tifying several enzymes
involved in peroxisomal
b-oxidation as antiviral. The
possibility that influenza virus
NS1 might interfere with the
peroxisomal step of DHA/
PD1 biosynthesis is rein-
forced by the identification of
peroxisomes as initial sites
for antiviral signaling (Dixit
et al., 2010).
While Amini-Bavil-Olyaee
and colleagues unveil a
novel IFITM3-cholesterol-
based host defense mecha-
nism against virus entry, Mor-
ita and colleagues discover
PD1 as a potent inhibitor of
influenza virus replication
exhibiting great therapeutic
potential. Together, these
new studies highlight the
increasing realization that ste-
rol/lipid composition and
metabolism play critical roles
in host-virus interactions at
different life cycle stages,
opening new and exciting
future research avenues. Lipidinvolvement during viral infections
currently is an emerging field, which,
with the recent advances in technology,
holds great promise to unravel novel
mechanisms and lipid factors involved in
host-virus interactions.REFERENCES
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In a recent Science paper, Teles et al. (2013) show that type I and II interferons (IFNs) are reciprocally
expressed in the polar immune forms of leprosy, with type I IFNs inducing IL-10 that interferes with the
antimycobacterial effects of type II IFNs (IFNg) at the site of infection.Leprosy, caused by the bacterium
Mycobacterium leprae, has a long tradi-
tion as a stigmatized disease, but also
serves as the paradigmatic human infec-
tion that evokes polarized cellular immune
responses. The two polar forms of
leprosy, termed tuberculoid and leproma-
tous, have clinical, microbiological, and
immunological distinctions. Tuberculoid
leprosy is characterized by few skin le-
sions, low numbers of bacteria in lesions,
and histologically well-formed granu-
lomas containing abundant CD4 T cells,
while lepromatous leprosy is character-
ized by numerous infiltrative skin lesions,
large numbers of bacteria in lesions, and
poorly formed granulomas with fewer
lymphocytes. Since the seminal discovery
that identified a predominance of Th1
CD4 T cells in lesions of tuberculoid
leprosy and Th2 cells in lepromatous
lesions (Salgame et al., 1991), which
activate the cellular and humoral immune
responses, respectively, further investiga-
tion has yielded evidence that the proin-
flammatory cytokine IL-12 (Sieling et al.,
1994) and multiple other cytokines are
differentially expressed at the site of dis-
ease in the polar forms of leprosy.
In a recent paper in Science, Teles et al.
present evidence that the anti-inflamma-
tory cytokine IL-10 induced by type I
interferons (IFNs) is a factor promoting
lepromatous leprosy (Teles et al., 2013)
(Figure 1). The authors first characterizedthe transcriptional signatures of skin le-
sions from both forms of leprosy. To
separate the broadly overlapping type I
and type II IFN-induced signatures that
they detected, they took advantage of
publicly available gene data sets specific
for responses to each type of IFN. They
revealed an overrepresentation of type I
IFN (IFNa/b)-induced genes, particularly
IL-10, in lepromatous lesions, whereas
tuberculoid lesions are significantly en-
riched in transcripts induced by type II
IFN (IFNg), including those of the
antimycobacterial vitamin D pathway.
Teles et al. also showed that the transcrip-
tional profile of reversal reaction (RR) le-
sions, which characterize a transition
from the lepromatous toward the tubercu-
loid end of the spectrum, clusters with
that of the latter. Interestingly, type I and
type II IFN-driven signatures seemed to
be mutually exclusive in each polar form
of the disease. Beyond leprosy, the au-
thors compared their results to recently
published studies of blood transcriptional
signatures in patients with active tuber-
culosis (Teles et al., 2013; Berry et al.,
2010; Maertzdorf et al., 2012) and pro-
posed a common type I IFN-inducible
gene program that correlates with
severity of mycobacterial infections. The
authors then strengthened their case by
measuring the increased levels of Ifnb,
one of the 14 type I IFNs, and Ifnar1, the
specific receptor for type I IFNs, tran-scripts, and proteins in lepromatous
versus tuberculoid or RR lesions. They
found a positive correlation between
type I IFNs and IL-10 mRNA levels and
colocalization of the corresponding pro-
teins in lepromatous lesions. To decipher
the functional correlation between these
cytokines, they showed in vitro that hu-
man blood monocytes produce type I
IFNs and IL-10 in response to live or son-
icated M. leprae and that the production
of IL-10 is at least partially dependent
on type I IFNs signaling through their
specific receptor. Finally, following a se-
ries of microarray analyses of skin lesions
and in vitro experiments, the authors
concluded that type I IFN-induced pro-
duction of IL-10 in lepromatous lesions
inhibits type II IFN-induced genes and
networks, such as antimicrobial peptides
or the vitamin D pathway, with a direct
consequence on the ability of mono-
cytes/macrophages to control the intra-
cellular growth of M. leprae.
The reciprocal changes in cytokine
expression in tuberculoid and leproma-
tous leprosy have revealed evidence for
complex cytokine regulatory networks at
the site of infection in a human disease,
yet they leave open an important ques-
tion: What is the initial determinant of the
polar immune responses to M. leprae?
Bacterial diversity is unlikely, given the
extremely high relatedness of leprosy
bacilli genomes worldwide (Monot et al.,13, April 17, 2013 ª2013 Elsevier Inc. 377
